Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Golan T, et al. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157963 Free PMC article. Clinical Trial.
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Lowery MA, et al. Among authors: golan t. Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8. Eur J Cancer. 2018. PMID: 29223478 Free PMC article. Clinical Trial.
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. O'Reilly EM, et al. Among authors: golan t. Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16. Cancer. 2018. PMID: 29338080 Free PMC article. Clinical Trial.
Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R. Golan T, et al. Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23. Int J Cancer. 2018. PMID: 29396858
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators. Hammel P, et al. Among authors: golan t. Ann Oncol. 2019 Dec 1;30(12):1959-1968. doi: 10.1093/annonc/mdz406. Ann Oncol. 2019. PMID: 31562758 Free PMC article. Clinical Trial.
219 results